285 related articles for article (PubMed ID: 25901018)
1. Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs.
Madan B; Virshup DM
Mol Cancer Ther; 2015 May; 14(5):1087-94. PubMed ID: 25901018
[TBL] [Abstract][Full Text] [Related]
2. Control of Wnt Receptor Turnover by R-spondin-ZNRF3/RNF43 Signaling Module and Its Dysregulation in Cancer.
Hao HX; Jiang X; Cong F
Cancers (Basel); 2016 Jun; 8(6):. PubMed ID: 27338477
[TBL] [Abstract][Full Text] [Related]
3. The Functional Landscape of Patient-Derived RNF43 Mutations Predicts Sensitivity to Wnt Inhibition.
Yu J; Yusoff PAM; Woutersen DTJ; Goh P; Harmston N; Smits R; Epstein DM; Virshup DM; Madan B
Cancer Res; 2020 Dec; 80(24):5619-5632. PubMed ID: 33067269
[TBL] [Abstract][Full Text] [Related]
4. Wnt Signaling and Drug Resistance in Cancer.
Zhong Z; Virshup DM
Mol Pharmacol; 2020 Feb; 97(2):72-89. PubMed ID: 31787618
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics and targeted therapy of WNT-related human diseases (Review).
Katoh M; Katoh M
Int J Mol Med; 2017 Sep; 40(3):587-606. PubMed ID: 28731148
[TBL] [Abstract][Full Text] [Related]
6. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.
Harb J; Lin PJ; Hao J
Curr Oncol Rep; 2019 Feb; 21(2):12. PubMed ID: 30715618
[TBL] [Abstract][Full Text] [Related]
7. [Screening for Chemical Suppressors of the Wnt/β-catenin Signaling Pathway].
Nishiya N
Yakugaku Zasshi; 2017; 137(2):133-136. PubMed ID: 28154320
[TBL] [Abstract][Full Text] [Related]
8. Targeting the WNT Signaling Pathway in Cancer Therapeutics.
Tai D; Wells K; Arcaroli J; Vanderbilt C; Aisner DL; Messersmith WA; Lieu CH
Oncologist; 2015 Oct; 20(10):1189-98. PubMed ID: 26306903
[TBL] [Abstract][Full Text] [Related]
9. Wnt Signaling in Cancer: Not a Binary ON:OFF Switch.
Flanagan DJ; Vincan E; Phesse TJ
Cancer Res; 2019 Dec; 79(23):5901-5906. PubMed ID: 31431458
[TBL] [Abstract][Full Text] [Related]
10. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
Yan M; Li G; An J
Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
[TBL] [Abstract][Full Text] [Related]
11. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
12. Wnt signaling as potential therapeutic target in lung cancer.
Yang J; Chen J; He J; Li J; Shi J; Cho WC; Liu X
Expert Opin Ther Targets; 2016 Aug; 20(8):999-1015. PubMed ID: 26882052
[TBL] [Abstract][Full Text] [Related]
13. Antagonizing canonical Wnt signaling pathway by recombinant human sFRP4 purified from E. coli and its implications in cancer therapy.
Ghoshal A; Ghosh SS
Mol Cell Biochem; 2016 Jul; 418(1-2):119-35. PubMed ID: 27334754
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs.
Vallée A; Lecarpentier Y; Vallée JN
Cells; 2019 Jul; 8(7):. PubMed ID: 31311204
[TBL] [Abstract][Full Text] [Related]
15. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
16. Wnt signaling and cancer development: therapeutic implication.
Paul S; Dey A
Neoplasma; 2008; 55(3):165-76. PubMed ID: 18348648
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.
Dzobo K; Thomford NE; Senthebane DA
OMICS; 2019 Nov; 23(11):517-538. PubMed ID: 31613700
[TBL] [Abstract][Full Text] [Related]
18. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials.
Neiheisel A; Kaur M; Ma N; Havard P; Shenoy AK
Int J Cancer; 2022 Mar; 150(5):727-740. PubMed ID: 34536299
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
Cheng X; Xu X; Chen D; Zhao F; Wang W
Biomed Pharmacother; 2019 Feb; 110():473-481. PubMed ID: 30530050
[TBL] [Abstract][Full Text] [Related]
20. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
